GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. GSK plc (NYSE:GSK) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 24 that GSK announced that Harmony Row Acquisition Co., an indirect wholly owned subsidiary, has formally launched a tender offer to acquire all outstanding Class A and Class B common shares of Nuvalent, Inc. (NASDAQ). Under the offer, Nuvalent shareholders would receive $124.00 per share in cash, subject to applicable withholding taxes and the conditions outlined in the offer documents. The tender offer is being carried out under the previously announced merger agreement signed on June 9, 2026, representing the next step toward completing the planned acquisition of Nuvalent.

In another commercial initiative, on June 1, GSK plc (NYSE:GSK)’s ViiV Healthcare introduced its PrEP Wisdom campaign to help people better understand long-acting injectable HIV prevention beyond dosing schedules alone. The awareness effort encourages informed decision-making by providing broader educational information about HIV pre-exposure prophylaxis (PrEP). The campaign also features television personality and longtime HIV and LGBTQ advocate Michelle Visage, supporting ViiV Healthcare’s efforts to expand public awareness and engagement around HIV prevention through educational outreach.

GSK plc (NYSE:GSK) is a global biopharmaceutical company developing vaccines and specialty medicines, with a focus on infectious diseases, HIV, respiratory/immunology, and oncology.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.